Table 3.
Multivariate analysis for OS
| HR (95% CI) | P | |
|---|---|---|
| a: Whole population (n = 111) | ||
| Overall survival | ||
| Age (≥56 y vs <56 y) | 1.155 (0.683–1.953) | 0.590 |
| FIGO stage (III/IV vs I/II) | 2.507 (0.621–10.127) | 0.197 |
| Residual tumour (any residual vs no residual) | 1.610 (0.875–2.962) | 0.126 |
| MVD (high vs low) | 0.818 (0.417–1.604) | 0.558 |
| VEGF (positive vs negative) | 0.420 (0.178–0.991) | 0.048 |
| FoxP3 mean number | 0.963 (0.778–1.191) | 0.727 |
| CD3 mean number | 1.000 (0.998–1.002) | 0.786 |
| CD4 mean number | 1.000 (0.999–1.001) | 0.925 |
| CD8 mean number | 1.000 (0.998–1.002) | 0.846 |
| Platinum response (Plat. Sens. vs Plat. Resist) | 0.229 (0.104–0.506) | < 0.001 |
| b: Only somatic-BRCA-tested population (n = 52) | ||
| Overall survival | ||
| Age (≥56 y vs <56 y) | 1.017 (0.410–2.524) | 0.971 |
| FIGO stage (III/IV vs I/II) | 1.506 (0.091–24.829) | 0.775 |
| Residual tumour (any residual vs no residual) | 1.417 (0.259–7.755) | 0.687 |
| MVD (high vs low) | 0.747 (0.243–2.291) | 0.609 |
| VEGF (positive vs negative) | 0.440 (0.127–1.526) | 0.196 |
| FoxP3 mean number | 0.683 (0.439–1.061) | 0.090 |
| CD3 mean number | 0.998 (0.994–1.001) | 0.132 |
| CD4 mean number | 0.997 (0.995–1.000) | 0.038 |
| CD8 mean number | 0.998 (0.994–0.997) | 0.438 |
| Somatic-BRCA status (BRCA–mut vs BRCA wt) | 0.354 (0.133–0.994) | 0.038 |
| Platinum response (Plat. Sens. vs Plat. Resist) | 0.216 (0.051–0.991) | 0.037 |
| c: Whole population (n = 111) | ||
| Progression-free interval | ||
| Age (≥56 y vs <56 y) | 1.067 (0.692–1.644) | 0.770 |
| FIGO stage (III/IV vs I/II) | 2.447 (0.892–6.711) | 0.082 |
| Residual tumour (any residual vs no residual) | 1.009 (0.568–1.794) | 0.974 |
| MVD (high vs low) | 1.445 (0.832–2.511) | 0.191 |
| VEGF (positive vs negative) | 0.945 (0.541–1.652) | 0.843 |
| FoxP3 mean number | 0.984 (0.832–1.162) | 0.845 |
| CD3 mean number | 1.000 (0.999–1.001) | 0.835 |
| CD4 mean number | 1.000 (0.999–1.001) | 0.698 |
| CD8 mean number | 1.000 (0.998–1.002) | 0.845 |
| d: Only somatic-BRCA-tested population (n = 52) | ||
| Progression-free interval | ||
| Age ( ≥ 56 y vs < 56 y) | 1.121 (0.542–2.318) | 0.759 |
| FIGO stage (III/IV vs I/II) | 18.261 (1.282–260.172) | 0.032 |
| Residual tumour (any residual vs no residual) | 1.391 (0.280–6.918) | 0.687 |
| MVD (high vs low) | 0.884 (0.375–2.081) | 0.777 |
| VEGF (positive vs negative) | 0.916 (0.400–2.095) | 0.834 |
| FoxP3 mean number | 0.868 (0.659–1.145) | 0.317 |
| CD3 mean number | 0.998 (0.995–1.001) | 0.159 |
| CD4 mean number | 0.996 (0.993–0.998) | 0.001 |
| CD8 mean number | 0.999 (0.995–1.003) | 0.719 |
| Somatic-BRCA status (BRCA-mut vs BRCA wt) | 0.982 (0.462–2.087) | 0.962 |
Multivariate analysis for OS carried out on (a) the whole patients’ population (n = 111), (b) only somatic-BRCA-tested population (n = 52) and multivariate analysis for PFI carried out on (c) the whole patients’ population (n = 111), (d) only somatic-BRCA-tested population (n = 52). Bold values indicate significant p values (<0.05)